Medical Journal Article Reports On Two Patients Who Experienced Severe Liver Damage Onset During Xarelto Treatment
Most adverse drug reaction case reports associated with the still relatively new anticoagulant Xarelto (rivaroxaban) involve serious bleeding side effects such as gastrointestinal (GI) bleeds and rectal bleeding as well as irreversible life-threatening trauma-induced atypical bleeding incidents.
A recent article, however, published by the medical journal JAMA Internal Medicine, "Symptomatic Hepatocellular Liver Injury With Hyperbilirubinemia in Two Patients Treated With Rivaroxaban", discusses a different serious Xarelto side effect: drug-induced liver injury / liver damage.
Strictly Confidential, No Obligation.
From a medical site summary about this recent Xarelto liver safety study, "Rivaroxaban and Liver Injury: Case Studies Add to Safety Questions", we get these facts:
A case study in JAMA Internal Medicine reports on two patients that experienced severe liver injury onset during treatment with the oral anticoagulant [Xarelto (rivaroxaban)]. The first patient was a 52-year-old man who developed severe lobular hepatitis two months after initiation of [Xarelto (rivaroxaban)] 10mg/day for the prevention of deep vein thrombosis (DVT) after internal fixation of a tibia fracture. The preserved lobular architecture and lack of fibrosis of portal tract were consistent with a drug-related liver injury.... The second patient, a 73-year-old woman prescribed 10mg/day of [Xarelto (rivaroxaban)] after a total knee replacement for the prevention of DVT, experienced mixed liver injury but liver enzyme levels and bilirubin concentration restored to normal levels after 14 days of [Xarelto (rivaroxaban)] cessation.... The authors speculate that [Xarelto (rivaroxaban)] was most likely the cause of drug-induced liver injury (DILI) in both patients and that physicians should be aware of this potentially severe adverse drug reaction. They also emphasize that a warning regarding symptomatic liver injury should be included in the drug label.
We will continue to watch for liver failure, drug-induced hepatitis, and liver damage drug injury cases possibly associated with Xarelto blood thinner treatment.